Welcome to our dedicated page for Neurosense Therapeutics SEC filings (Ticker: NRSNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to present SEC-related information for NeuroSense Therapeutics Ltd. in connection with the NRSNW symbol. NeuroSense is a clinical-stage biotechnology company that describes its focus as discovering and developing treatments for debilitating neurodegenerative diseases, including ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead candidate, PrimeC, is a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, designed to target multiple mechanisms involved in ALS and Alzheimer's disease.
While no specific SEC filings are listed in the available data for this symbol, investors commonly look to regulatory documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K to better understand a company’s business description, risk factors and program updates. For a company like NeuroSense, such filings can provide additional detail on its clinical-stage pipeline, including PrimeC, and on its strategy to develop combined therapies targeting multiple pathways associated with neurodegenerative diseases.
On Stock Titan, the SEC filings page is designed to surface these documents as they become available from EDGAR, along with AI-powered summaries that explain key sections in clearer language. When filings are present, users can review disclosures on topics such as clinical development progress, research activities and other company updates, and can also access insider transaction reports on Form 4 when applicable.
As filings for NRSNW are recorded, this page will help organize them by form type and date, and AI-generated insights will highlight important points so readers can more quickly understand how NeuroSense describes its business, programs and associated risks in its official SEC documents.
Binder Hagit reported acquisition or exercise transactions in this Form 4 filing.
NeuroSense Therapeutics Ltd. granted General Manager Hagit Binder 200,000 Ordinary Shares as a share-based compensation award, recorded at a price of $0.0000 per share. Following this grant, Binder directly holds 521,806 Ordinary Shares.
The award consists of restricted shares that vest in equal quarterly installments over a two-year period starting on March 26, 2026, conditioned on Binder’s continued service with the company at each vesting date. To qualify for certain Israeli tax benefits under Section 102, the securities must be registered in the name of a trustee, but they are reported here as directly owned by Binder.
NeuroSense Therapeutics furnished a report describing regulatory and clinical progress for its lead drug candidate, PrimeC, targeting ALS and Alzheimer’s disease. A pre-New Drug Submission meeting with Health Canada has been rescheduled to May 2026 so the company can include additional clinical, biomarker and survival data, aiming to strengthen its case under Canada’s conditional approval pathway (NOC/c).
The company also expects to report clinical and biomarker results from its Alzheimer’s study in the coming weeks. Management believes the enhanced data package and upcoming readouts could support a more constructive regulatory dialogue and mark important potential value inflection points across its ALS and Alzheimer’s programs during 2026.
NeuroSense Therapeutics Ltd. director Christine A. Pellizzari filed an initial ownership report showing existing equity interests rather than new trades. The filing lists options to purchase 72,000 Ordinary Shares at an exercise price of $1.43 per share, expiring on March 10, 2032, which are fully vested and exercisable. It also discloses direct holdings of Ordinary Shares, including restricted shares that vest on December 30, 2026 and January 30, 2027, subject to continued service and achievement of specified business milestones.
NeuroSense Therapeutics reported that results from its multinational Phase 2b trial of PrimeC in amyotrophic lateral sclerosis (ALS) have been published in JAMA Neurology. The randomized, double-blind, placebo-controlled study enrolled 68 participants and included a 6‑month blinded period followed by a 12‑month open‑label extension.
Participants who received PrimeC from the outset maintained a 7.92‑point functional advantage on the ALSFRS‑R scale at 18 months, representing over 36% slowing of disease progression (p=0.007), with the largest benefit in the bulbar domain (p=0.001). ALS complication‑free survival showed a 64% relative risk reduction favoring early treatment (p=0.02).
The trial also showed biological activity consistent with PrimeC’s multi‑pathway mechanism, including favorable changes in iron metabolism markers and significant downregulation of ALS‑associated microRNAs. These data, together with good safety, helped shape NeuroSense’s Phase 3 trial of PrimeC, which has received FDA clearance to proceed.
NeuroSense Therapeutics Ltd. held a Special Meeting of Shareholders on March 10, 2026. At this meeting, shareholders approved a resolution to amend the company’s articles of association in order to increase the company’s registered share capital, expanding the amount of equity the company is authorized to issue in the future.
The report also states that this information is incorporated by reference into NeuroSense’s existing registration statements on Form S-8 and Form F-3, meaning those shelf and employee benefit registrations now reflect the updated corporate authorization.
NeuroSense Therapeutics reported new long-term survival data from its completed Phase 2b trial of PrimeC in amyotrophic lateral sclerosis (ALS). Patients treated continuously with PrimeC showed an estimated median survival of 36.3 months versus 21.4 months for those initially on placebo, an improvement of over 14 months and about a 70% increase in median survival. A log-rank test showed statistically significant separation between treatment arms (p = 0.0218), and a Cox model associated PrimeC with a 65% reduction in risk of death versus placebo (hazard ratio 0.35; 95% CI: 0.17–0.71; p = 0.0037). The randomized, double-blind, placebo-controlled trial in 68 ALS patients had previously demonstrated slowed disease progression and favorable safety. NeuroSense believes these survival results strengthen the case for advancing PrimeC into pivotal late-stage development.
NeuroSense Therapeutics Ltd. is asking shareholders to approve an amendment to its Articles of Association to increase its registered share capital to 200 million ordinary shares, no par value. The registered share capital is currently 90 million ordinary shares.
As of February 11, 2026, the company had approximately 39 million ordinary shares available for future issuance after accounting for outstanding options, warrants and RSU grants. The board states that the larger share pool is intended to maintain flexibility for strategic financings and other issuances to support continued development of PrimeC, including planned Phase 3 activities.
The proposal will be presented at a Special Meeting of Shareholders scheduled for March 10, 2026, at 4:00 p.m. (Israel time) in Herzliya. Shareholders of record at the close of business on February 17, 2026 are entitled to notice and to vote, and the board unanimously recommends voting in favor.
NeuroSense Therapeutics filed a Form 6-K to highlight a new Australian patent grant for its lead drug candidate PrimeC. The Australian Patent Office granted Patent No. 2022370513, covering compositions combining ciprofloxacin and celecoxib, extending patent protection for PrimeC in Australia through October 2042 and reinforcing a previously granted U.S. patent.
PrimeC is a proprietary fixed-dose, extended-release oral formulation designed to deliver ciprofloxacin and celecoxib in a synchronized way, targeting multiple disease pathways in amyotrophic lateral sclerosis (ALS) and potentially Alzheimer’s disease and other neurodegenerative conditions. NeuroSense describes PrimeC as Phase 3-ready in ALS, following positive Phase 2b results and FDA clearance of a pivotal Phase 3 protocol.
The company frames this Australian patent as part of a broader global intellectual property strategy intended to support the long-term development and potential commercialization of PrimeC across major markets.